Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF4E | P06730 | 17/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14797131 | 0.91 | EIF4E (0.71) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL14797478 | 0.87 | EIF4E (0.74) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL14797390 | 0.86 | EIF4E (0.68) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL17132709 | 0.85 | EIF4E (0.61) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL14797513 | 0.84 | EIF4E (0.71) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL14797442 | 0.84 | EIF4E (0.69) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL14797521 | 0.83 | EIF4E (0.71) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL14797353 | 0.83 | EIF4E (0.70) | EIF4EKDM4ENPC1RAB9AMEN1 | |
| SCHEMBL14797373 | 0.82 | EIF4E (1.00) | EIF4E | |
| SCHEMBL14797186 | 0.81 | EIF4E (0.77) | EIF4EKDM4ENPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9073881-B2 | Benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| WO-2013041468-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-28 | — | — | WO | disclosed |
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2013-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079346-A1 | BENZOIC ACID DERIVATIVES | EIF4EBP1, EIF4E, EIF4A2 | EIF4E 2/4885KDM4E 390/4885NPC1 2598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.